- Main
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
- Penson, Peter E;
- Bruckert, Eric;
- Marais, David;
- Reiner, Željko;
- Pirro, Matteo;
- Sahebkar, Amirhossein;
- Bajraktari, Gani;
- Mirrakhimov, Erkin;
- Rizzo, Manfredi;
- Mikhailidis, Dimitri P;
- Sachinidis, Alexandros;
- Gaita, Dan;
- Latkovskis, Gustavs;
- Mazidi, Mohsen;
- Toth, Peter P;
- Pella, Daniel;
- Alnouri, Fahad;
- Postadzhiyan, Arman;
- Yeh, Hung‐I;
- Mancini, GB John;
- von Haehling, Stephan;
- Banach, Maciej;
- Acosta, Julio;
- Al‐Khnifsawi, Mutaz;
- Alnouri, Fahad;
- Amar, Fahma;
- Atanasov, Atanas G;
- Bajraktari, Gani;
- Banach, Maciej;
- Bhaskar, Sonu;
- Bytyçi, Ibadete;
- Bjelakovic, Bojko;
- Bruckert, Eric;
- Cafferata, Alberto;
- Ceska, Richard;
- Cicero, Arrigo FG;
- Collet, Xavier;
- Daccord, Magdalena;
- Descamps, Olivier;
- Djuric, Dragan;
- Durst, Ronen;
- Ezhov, Marat V;
- Fras, Zlatko;
- Gaita, Dan;
- Hernandez, Adrian V;
- Jones, Steven R;
- Jozwiak, Jacek;
- Kakauridze, Nona;
- Kallel, Amani;
- Katsiki, Niki;
- Khera, Amit;
- Kostner, Karam;
- Kubilius, Raimondas;
- Latkovskis, Gustavs;
- Mancini, GB John;
- Marais, A David;
- Martin, Seth S;
- Martinez, Julio Acosta;
- Mazidi, Mohsen;
- Mikhailidis, Dimitri P;
- Mirrakhimov, Erkin;
- Miserez, Andre R;
- Mitchenko, Olena;
- Mitkovskaya, Natalya P;
- Moriarty, Patrick M;
- Nabavi, Seyed Mohammad;
- Nair, Devaki;
- Panagiotakos, Demosthenes B;
- Paragh, György;
- Pella, Daniel;
- Penson, Peter E;
- Petrulioniene, Zaneta;
- Pirro, Matteo;
- Postadzhiyan, Arman;
- Puri, Raman;
- Reda, Ashraf;
- Reiner, Željko;
- Radenkovic, Dina;
- Rakowski, Michał;
- Riadh, Jemaa;
- Richter, Dimitri;
- Rizzo, Manfredi;
- Ruscica, Massimiliano;
- Sahebkar, Amirhossein;
- Sattar, Naveed;
- Serban, Maria‐Corina;
- Shehab, Abdullah MA;
- Shek, Aleksandr B;
- Sirtori, Cesare R;
- Stefanutti, Claudia;
- Tomasik, Tomasz;
- Toth, Peter P;
- Viigimaa, Margus;
- Valdivielso, Pedro;
- Vinereanu, Dragos;
- Vohnout, Branislav;
- von Haehling, Stephan;
- Vrablik, Michal;
- Wong, Nathan D;
- Yeh, Hung‐I;
- Zhisheng, Jiang;
- Zirlik, Andreas
Published Web Location
https://doi.org/10.1002/jcsm.12960Abstract
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.